Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [10]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 11503-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#11503-1-AP, RRID:AB_2262942
- Product name
- FRS2 antibody
- Antibody type
- Polyclonal
- Description
- FRS2 antibody (Cat. #11503-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IF, IHC, WB, ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references FGF9, a Potent Mitogen, Is a New Ligand for Integrin αvβ3, and the FGF9 Mutant Defective in Integrin Binding Acts as an Antagonist.
Functional Distinctions of Endometrial Cancer-Associated Mutations in the Fibroblast Growth Factor Receptor 2 Gene.
FGF9, a potent mitogen, is a new ligand for integrin αvβ3, and the FGF9 mutant defective in integrin binding acts as an antagonist.
Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4.
Inhibition of autophagy potentiates the cytotoxicity of the irreversible FGFR1-4 inhibitor FIIN-2 on lung adenocarcinoma.
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1.
Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547.
MiR-339 inhibits proliferation of pulmonary artery smooth muscle cell by targeting FGF signaling.
Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma.
High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma.
Chang CC, Takada YK, Cheng CW, Maekawa Y, Mori S, Takada Y
Cells 2024 Feb 7;13(4)
Cells 2024 Feb 7;13(4)
Functional Distinctions of Endometrial Cancer-Associated Mutations in the Fibroblast Growth Factor Receptor 2 Gene.
Dixit G, Pappas BA, Bhardwaj G, Schanz W, Maretzky T
Cells 2023 Sep 7;12(18)
Cells 2023 Sep 7;12(18)
FGF9, a potent mitogen, is a new ligand for integrin αvβ3, and the FGF9 mutant defective in integrin binding acts as an antagonist.
Chang CC, Takada YK, Cheng CW, Maekawa Y, Mori S, Takada Y
bioRxiv : the preprint server for biology 2023 Dec 2;
bioRxiv : the preprint server for biology 2023 Dec 2;
Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4.
Shao M, Chen X, Yang F, Song X, Zhou Y, Lin Q, Fu Y, Ortega R, Lin X, Tu Z, Patterson AV, Smaill JB, Chen Y, Lu X
Journal of medicinal chemistry 2022 Mar 24;65(6):5113-5133
Journal of medicinal chemistry 2022 Mar 24;65(6):5113-5133
Inhibition of autophagy potentiates the cytotoxicity of the irreversible FGFR1-4 inhibitor FIIN-2 on lung adenocarcinoma.
Jia X, Xin M, Xu J, Xiang X, Li X, Jiao Y, Wang L, Jiang J, Pang F, Zhang X, Zhang J
Cell death & disease 2022 Aug 30;13(8):750
Cell death & disease 2022 Aug 30;13(8):750
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1.
Mouron S, Manso L, Caleiras E, Rodriguez-Peralto JL, Rueda OM, Caldas C, Colomer R, Quintela-Fandino M, Bueno MJ
Breast cancer research : BCR 2021 Feb 12;23(1):21
Breast cancer research : BCR 2021 Feb 12;23(1):21
Transcriptomics and Transposon Mutagenesis Identify Multiple Mechanisms of Resistance to the FGFR Inhibitor AZD4547.
Kas SM, de Ruiter JR, Schipper K, Schut E, Bombardelli L, Wientjens E, Drenth AP, de Korte-Grimmerink R, Mahakena S, Phillips C, Smith PD, Klarenbeek S, van de Wetering K, Berns A, Wessels LFA, Jonkers J
Cancer research 2018 Oct 1;78(19):5668-5679
Cancer research 2018 Oct 1;78(19):5668-5679
MiR-339 inhibits proliferation of pulmonary artery smooth muscle cell by targeting FGF signaling.
Chen J, Cui X, Li L, Qu J, Raj JU, Gou D
Physiological reports 2017 Sep;5(18)
Physiological reports 2017 Sep;5(18)
Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma.
Zhang K, Chu K, Wu X, Gao H, Wang J, Yuan YC, Loera S, Ho K, Wang Y, Chow W, Un F, Chu P, Yen Y
Cancer research 2013 Feb 15;73(4):1298-307
Cancer research 2013 Feb 15;73(4):1298-307
High-resolution genomic mapping reveals consistent amplification of the fibroblast growth factor receptor substrate 2 gene in well-differentiated and dedifferentiated liposarcoma.
Wang X, Asmann YW, Erickson-Johnson MR, Oliveira JL, Zhang H, Moura RD, Lazar AJ, Lev D, Bill K, Lloyd RV, Yaszemski MJ, Maran A, Oliveira AM
Genes, chromosomes & cancer 2011 Nov;50(11):849-58
Genes, chromosomes & cancer 2011 Nov;50(11):849-58
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- MCF-7 cells were subjected to SDS PAGE followed by western blot with 11503-1-AP( FRS2 Antibody) at dilution of 1:1000
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The FRS2 antibody from Proteintech is a rabbit polyclonal antibody to a peptide of human FRS2. This antibody recognizes human,mouse,rat antigen. The FRS2 antibody has been validated for the following applications: ELISA, IHC, WB analysis.
